These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19965548)

  • 21. The role of vitamin D replacement therapy in serum FGF23 concentration in children with myelomeningocele compared with healthy children - a preliminary study.
    Bagińska J; Liszewska A; Korzeniecka-Kozerska A
    J Pediatr Endocrinol Metab; 2019 Nov; 32(11):1259-1264. PubMed ID: 31465293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
    Xu J; Yang Y; Ma L; Fu P; Peng H
    Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
    Takasugi S; Akutsu M; Nagata M
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):140-4. PubMed ID: 24975224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
    Serra AL; Wuhrmann C; Wüthrich RP
    Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
    Nakai K; Komaba H; Fukagawa M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
    Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
    Floege J; Raggi P; Block GA; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Chertow GM;
    Nephrol Dial Transplant; 2010 Jun; 25(6):1916-23. PubMed ID: 20110249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
    Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V
    Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
    Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
    Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
    Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.